Generic Name and Formulations:
Bosutinib 100mg, 500mg; tabs.
Indications for BOSULIF:
Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
Initially 500mg once daily with food. Continue until disease progression or patient intolerance. Consider dose escalation to 600mg once daily in patients who do not reach complete hematological response (CHR) by Week 8 or a complete cytogenetic response (CCyR) by Week 12, who did not have Grade 3 or higher adverse reactions. Adjust dose for hematologic and non-hematologic toxicity: see full labeling. Hepatic impairment: initially 200mg daily. Renal impairment (CrCl 30–50mL/min): initially 400mg daily; (CrCl <30mL/min): initially 300mg daily.
<18yrs: not established.
Tyrosine kinase inhibitor.
Monitor and manage GI toxicity, fluid retention; withhold, reduce dose, or discontinue as necessary. Perform CBC weekly for first month, then monthly; hepatic enzyme tests monthly for first three months (more frequently if transaminase elevations occur); withhold, reduce dose, or discontinue as necessary. Monitor renal function at baseline and during therapy; consider adjusting dose if renal impairment occurs. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.
Potentiated by concomitant strong or moderate CYP3A and/or P-gp inhibitors (eg, ritonavir, indinavir, nelfinavir, saquinavir, ketoconazole, boceprevir, telaprevir, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone, conivaptan, fluconazole, darunavir, erythromycin, diltiazem, atazanavir, aprepitant, amprenavir, fosamprenavir, crizotinib, imatinib, verapamil, grapefruit products, ciprofloxacin); avoid. Antagonized by concomitant strong or moderate CYP3A inducers (eg, rifampin, phenytoin, carbamazepine, St. John’s Wort, rifabutin, phenobarbital, bosentan, nafcillin, efavirenz, modafinil, etravirine); avoid. Antagonized by proton pump inhibitors (eg, lansoprazole); consider short-acting antacids or H2 blockers instead; separate dosing by more than 2hrs. May potentiate drugs that are P-gp substrates (eg, digoxin).
Diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, fatigue; fluid retention (monitor), hepatic toxicity.
Hepatic (CYP3A4); 94% protein bound.
Fecal (primary), renal.
Tabs 100mg—120; 500mg—30
- 100mg tablets (Qty:45)
- appx. price $3829.00
- McDonald's and the Microbiome: What Effect Does Junk Food Have on Gut Bacteria?
- When the Doctor is Depressed: One Clinician Tells His Story
- Spice + Statin Likely Culprit in Patient with Acute Hepatitis
- Most Distinctive Causes of Death Mapped by U.S. State
- First Non-Surgical Tx for "Double Chin" Gains FDA Approval
- Heart Rate May Be an Indicator of Future Diabetes Risk
- Probiotic Mixture VSL#3 Shows Promise for Crohn's Recurrence
- Study: Beloranib Appears Safe, Efficacious for Weight Loss in Obesity
- Progress Toward Mind-Controlled Robotic Limbs
- Response to Resistance Exercise Depends on a Person's Genetic Risk for Obesity